Fig 3.
Potentiation of the anti-HIV-1 activity of ACV by ribavirin in human lymphoid tissue. Donor-matched tissue blocks (27 blocks from each donor) were inoculated with HIV-1LAI.04 and treated with ACV (0.3, 3, or 10 μM) in the absence or presence of 10 μM ribavirin. Replication of HIV-1 was evaluated by p24gag core antigen release in pooled medium bathing 27 tissue blocks using a bead-based assay. The percentage of HIV-1 inhibition was evaluated by comparing viral replication in drug-treated tissues with that in untreated donor-matched control tissues. Presented are means ± SEM of HIV-1LAI.04 inhibition in 27 human tissue blocks from each of 6 to 10 donors, relative to results for matched untreated tissues (n = 6 for experiments performed with 0.3 μM ACV; n = 10 for experiments performed with 3 or 10 μM ACV). An asterisk denotes a statistically significant difference (P < 0.05) in HIV-1LAI.04 inhibition between untreated and ribavirin-treated tissues.